GlobeNewswire – Page 1031

Notice to attend Extraordinary General Meeting in INQ Group AB (publ)

Posted on October 8, 2026 by Ravi Shankar

Purpose of the EGM
The Board is proposing three things:

Warrants and convertibles within the existing limit. The AGM 2026 authorised the Board to issue new shares only. Authorisations at previous annual general meetings also covered warrants and convertibles. The proposal restores that flexibility, within the same 390,000,000 limit, giving the Board the full range of instruments to raise capital on the best available terms and to meet the needs of different types of investors.
Conversion of Tranche 7 by the Board and management. The Chairman, the Chief Executive Officer and other members of management have taken part in Tranche 7 of the Company’s convertible loan by setting off accrued fees and salary instead of taking them in cash. Tranche 7 converts at SEK 0.16 per share. Because they are directors and employees, shares issued to them on conversion require shareholder approval. The EGM is also asked to approve conversion of Tranche 7 by the other participants. All shares on conversion of Tranche 7 are counted within the 390,000,000 limit.
Reverse split after conversion of Tranches 1 to 5. As resolved by the AGM 2026, the 1:100 reverse split was to be carried out before the share capital measures and the issue of shares on conversion of Tranches 1 to 5 of the convertible loan. The proposal allows the reverse split to take place after those shares have been issued, at the quota value applying at that time, with the Board setting the timing.

The EGM does not seek authority to issue any more shares than the 390,000,000 already authorised by the Annual General Meeting 2026. The proposals change the form in which that existing authority can be used and the order in which steps already approved are carried out.

After deducting up to approximately 49.2 million shares for conversion of Tranche 7, including interest, approximately 340.8 million shares remain available to the Board from the 390 million shares approved authorised by the Annual General Meeting 2026, corresponding to a maximum dilution of approximately 16.7 per cent as calculated in the notice.

Kevin Adeson, Chairman of INQ Group AB, commented:

“Warrants and convertibles give the Board the flexibility to use the authority shareholders granted in July in the most effective way. This gives us more flexibility to be creative with the capital formation tools available to access and provide our company with strategic growth capital. The Board and management, have chosen to invest in the company by taking compensation due to them in the form of Tranche 7 convertible instead of cash. We are asking shareholders to approve that conversion. We are excited to see INQ now at its inflection point and we are putting our own compensation back into the company.”

The above is a summary only. The complete agenda, the full terms of each proposed resolution, and the applicable majority requirements are set out in the notice of the Extraordinary General Meeting below, which is the governing document. In the event of any inconsistency between this summary and the notice, the notice prevails.

The shareholders of INQ Group AB (publ), reg. no. 556532-3929 (the “Company”) are hereby invited to attend the Extraordinary General Meeting (the “EGM”) to be held on Friday, 30 October 2026 at 10:00 a.m. at the premises of Setterwalls Advokatbyrå, Sturegatan 10 in Stockholm, Sweden.

Notification of participation

Shareholders wishing to attend the EGM must:

be entered as shareholders in the share register maintained by Euroclear Nordics AB no later than on Thursday, 22 October 2026; and
notify the Company of their intention to participate no later than on Monday, 26 October 2026.

Attendance is to be notified by email to Eric.Torstensson@setterwalls.se. The notification should state name, social security number/corporate identification number and registered number of shares. To facilitate admittance to the EGM, proxies, registration certificates and other authorisation documents should be submitted by email to Eric.Torstensson@setterwalls.se no later than Monday, 26 October 2026. The Company provides proxy forms on the Company’s web page www.inq.ai.

To be entitled to participate at the EGM, shareholders who have had their shares registered through nominees (Sw. förvaltare) must, in addition to notifying the Company of their intention to participate at the EGM, have their shares registered in their own name so that the shareholder is entered into the share register per the record date above. Such registration may be temporary (so-called voting rights registration) (Sw. rösträttsregistrering) and is requested with the nominee in accordance with the nominee’s routines at such time in advance as the nominee determines. Voting rights registrations made no later than Monday, 26 October 2026, being four banking days prior to the EGM, are considered when preparing the share register.

Proxies

If shareholders wish to attend the EGM through a proxy, a written and dated power of attorney signed by the shareholder must be enclosed with the notification. The power of attorney form is available on the Company’s website www.inq.ai. If the shareholder is a legal entity, a registration certification or an equivalent authorisation document must be enclosed along with the notification.

Proposed agenda

Opening of the Meeting and election of Chairman
Preparation and approval of voting list
Approval of the agenda
Election of one or two persons to verify the minutes
Determination of whether the Meeting has been duly convened
Resolution on an authorisation for the Board of Directors to resolve on the issue of new shares, warrants and convertibles
Resolution on amendment of the resolution on consolidation of shares (reverse split 1:100) adopted by the Annual General Meeting 2026
Resolution on a directed issue of new shares with payment by set-off to members of the Board of Directors and the Chief Executive Officer in respect of participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement
Resolution on a directed issue of new shares with payment by set-off to other subscribers for participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement
Closing of the Meeting

Proposals

Opening of the Meeting and election of Chairman (item 1)

The Board of Directors proposes that Jörgen S. Axelsson, or in his absence the person appointed by the Board of Directors, be elected as Chairman of the Meeting.

Authorisation for the Board of Directors to resolve on the issue of new shares, warrants and convertibles (item 6)

The Board of Directors proposes that the EGM authorises the Board of Directors to resolve, on one or more occasions during the period until the next Annual General Meeting, with or without deviation from the shareholders’ preferential rights, against cash payment, payment in kind or by way of set-off, to issue new ordinary shares, warrants and/or convertibles by way of directed issue and/or rights issue. The aggregate number of ordinary shares that may be issued under this authorisation, including ordinary shares that may be subscribed for or converted into under warrants or convertibles issued under this authorisation, shall not exceed 390,000,000 ordinary shares less the maximum number of ordinary shares that may be issued under items 8 and 9, less the maximum number of ordinary shares required for the issue of new shares on conversion of accrued and unpaid interest relating to Tranche 6 held by members and former members of the Board of Directors, being 873,566 ordinary shares, and less the number of ordinary shares issued under the authorisation resolved by the Annual General Meeting 2026 under item 14(e) before the EGM. On that basis, and disregarding any issues under item 14(e) before the EGM, the authorisation comprises a maximum of 339,944,716 ordinary shares, corresponding to a maximum dilution of approximately 16.9 per cent calculated as the maximum number of new shares divided by the number of shares in the Company following registration of the issues resolved on at the Annual General Meeting 2026, the directed issues under items 8 and 9 and the further issues of new shares required for conversion in full of the outstanding principal and maximum accrued interest under the Amended and Restated Secured Convertible Agreement, being 2,013,464,088 ordinary shares. This authorisation replaces the authorisation resolved by the Annual General Meeting 2026 under item 14(e), which shall cease to apply to the extent not already exercised.

The basis for the issue price shall be the market conditions prevailing at the time of the resolution on the relevant issue, and the issue price, the subscription price under any warrants and the conversion price under any convertibles shall be determined on market terms. This does not apply to an issue of new ordinary shares resolved on in order to satisfy conversion under the Company’s existing convertible investment agreements, including the Amended and Restated Secured Convertible Agreement, where the subscription price shall instead be the conversion price agreed under the relevant agreement, applying the fixed exchange rate agreed under that agreement, and the basis for the subscription price is that contractual conversion price. The purpose of this authorisation and the reason for any deviation from the shareholders’ preferential rights is to increase the Company’s flexibility to finance its ongoing operations and at the same time broaden and strengthen the Company’s shareholder base with strategic or long-term investors, and to enable the Company to satisfy conversion under its existing convertible investment agreements.

A valid resolution under this item 6 requires that the resolution be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the EGM. This item is not conditional upon any other item on the agenda. This authorisation does not cover issues directed to the category of persons covered by Chapter 16 of the Swedish Companies Act (2005:551), which require a resolution of the general meeting.

Resolution on amendment of the resolution on consolidation of shares (reverse split 1:100) adopted by the Annual General Meeting 2026 (item 7)

The Annual General Meeting 2026 resolved under item 20 on a consolidation of the Company’s shares (1:100), whereby one hundred (100) shares are combined into one (1) share. That resolution states that the consolidation is carried out before the reduction of the Company’s share capital and is based on the then current share quota value of SEK 0.13 per share, resulting in a new share quota value of SEK 13 per share. Following the issues of new shares, the reduction of the share capital and the bonus issue resolved on at the Annual General Meeting 2026, and the share issues proposed under items 6, 8 and 9 above, the share quota value at the time of the consolidation will not correspond to SEK 0.13 per share and the resulting quota value will not correspond to SEK 13 per share.

The Board of Directors therefore proposes that the EGM resolves to amend the resolution of the Annual General Meeting 2026 under item 20 so that the consolidation of shares (1:100) is carried out on the basis of the share quota value applicable at the time of the consolidation, and that the Board of Directors is authorised to determine the applicable share quota value and the resulting share quota value following the consolidation, in each case as it follows from the Company’s registered share capital and registered number of shares at that time. The number of shares in the Company shall, as resolved by the Annual General Meeting 2026, be reduced by combining one hundred (100) shares into one (1) share. The Board of Directors shall be authorised to determine the record date for the consolidation, to fall after the resolution has been registered with the Swedish Companies Registration Office, and otherwise to take the measures required to implement the consolidation, including determining the order in which the consolidation and the registration of the share issues are carried out.

The other terms of the resolution of the Annual General Meeting 2026 under item 20 shall remain unchanged, including that excess shares shall pass into the ownership of the Company on the record date and be sold at the Company’s expense through a securities institution, with the proceeds distributed among the shareholders concerned in proportion to their respective participation in the shares sold. Further information on the procedure for the consolidation will be announced in connection with the Board of Directors resolving on the record date.

The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make such minor adjustments to the resolution as may prove necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Nordics AB, including reducing the number of shares issued under items 8 and 9 by up to ninety-nine (99) shares in aggregate so that the total number of ordinary shares in the Company at the time of the consolidation amounts to a whole multiple of one hundred (100). The resolution under this item 7 is conditional upon the amendment of § 5 of the articles of association resolved by the Annual General Meeting 2026 under item 19, whereby the number of shares shall be not less than 10,000,000 and not more than 40,000,000, having been registered with the Swedish Companies Registration Office, and the consolidation shall not be carried out until that registration has taken place. A valid resolution under this item 7 requires a simple majority of the votes cast at the EGM, as the resolution does not entail an amendment of the articles of association.

Directed issue of new shares with payment by set-off to members of the Board of Directors and the Chief Executive Officer in respect of participations in Tranche 7 (item 8)

The Board of Directors proposes that the EGM resolves on a directed issue of a maximum of 12,280,059 new ordinary shares in aggregate to the persons set out below, with deviation from the shareholders’ preferential rights. The right to subscribe for the new shares shall accrue only to those persons, who have subscribed for participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement by way of set-off of accrued and unpaid directors’ fees and salary. The subscription price shall be SEK 0.16 per share, being the contractual conversion price for Tranche 7, applying a fixed exchange rate of SEK/USD 9.05 to claims denominated in USD, and exceeds the share quota value of SEK 0.10 per share. The number of shares to be issued to each subscriber shall be determined on the basis of the amount of the relevant claim, comprising the principal amount of the subscriber’s participation in Tranche 7 together with accrued and unpaid interest, outstanding as at the date of the Board of Directors’ statement pursuant to Chapter 13, Section 7 of the Swedish Companies Act (2005:551), divided by the subscription price at that fixed exchange rate, rounded down to the nearest whole share. Any interest accruing after that date is not covered by this resolution and remains outstanding under the Amended and Restated Secured Convertible Agreement.

The subscribers and the principal amounts of their participations in Tranche 7 are Kevin Adeson, Chairman of the Board of Directors, USD 89,750, Jonathan Faiman, Chief Executive Officer, USD 75,000, and Hans Haywood, USD 35,000, in aggregate USD 199,750.

Payment for the new shares shall be made solely by way of set-off of the relevant subscriber’s claim against the Company. Subscription and payment by set-off shall be made within two (2) months from the date of the EGM, with the Board of Directors entitled to extend the subscription and payment period. The new shares shall entitle to dividends for the first time on the first record date for dividends occurring after the registration of the new shares with the Swedish Companies Registration Office. The reason for the deviation from the shareholders’ preferential rights is to enable the relevant persons to convert their existing claims against the Company into ordinary shares, thereby fulfilling the Company’s contractual obligations to those lenders and strengthening the Company’s balance sheet by converting debt into equity. The basis for the subscription price is the contractual conversion price agreed under the Amended and Restated Secured Convertible Agreement. The Board of Directors’ statement pursuant to Chapter 13, Section 7 of the Swedish Companies Act, together with the auditor’s report on that statement pursuant to Chapter 13, Section 8 of the Swedish Companies Act, will be made available in accordance with the Swedish Companies Act.

As the new shares are issued to members of the Board of Directors and the Chief Executive Officer, the issue is directed to the category of persons covered by Chapter 16 of the Swedish Companies Act (2005:551). A resolution under this item 8 is therefore valid only if it is supported by shareholders holding not less than nine-tenths of both the votes cast and the shares represented at the EGM. That majority requirement applies to this item only. This resolution is not conditional upon any other item on the agenda, and no other item is conditional upon this item 8. The shares under this item 8 fall within the limit of 390,000,000 shares described under item 6 and have been deducted in calculating the maximum number of shares under that item. The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make such minor adjustments to the resolution as may prove necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Nordics AB.

Directed issue of new shares with payment by set-off to other subscribers for participations in Tranche 7 (item 9)

The Board of Directors proposes that the EGM resolves on a directed issue of a maximum of 36,901,659 new ordinary shares in aggregate to the subscribers for participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement set out below, none of whom belongs to the category of persons covered by Chapter 16 of the Swedish Companies Act (2005:551), with deviation from the shareholders’ preferential rights. The subscription price shall be SEK 0.16 per share, being the contractual conversion price for Tranche 7, applying a fixed exchange rate of SEK/USD 9.05 to claims denominated in USD, and exceeds the share quota value of SEK 0.10 per share. The number of shares to be issued to each subscriber shall be determined on the basis of the amount of the relevant claim, comprising the principal amount of the subscriber’s participation in Tranche 7 together with accrued and unpaid interest, outstanding as at the date of the Board of Directors’ statement pursuant to Chapter 13, Section 7 of the Swedish Companies Act, divided by the subscription price at that fixed exchange rate, rounded down to the nearest whole share. Any interest accruing after that date is not covered by this resolution and remains outstanding under the Amended and Restated Secured Convertible Agreement.

The subscribers and the principal amounts of their participations in Tranche 7 are Gunnar S. Overstrom III, USD 175,000, GJR II, USD 75,000, Vayu Investors LLC, USD 250,000, Malin Garner, USD 75,000, Brera Advisors LLP, USD 10,000, and a limited number of other investors with whom the Company has a business relationship, in aggregate USD 15,250, in aggregate USD 600,250.

As the new shares are issued with deviation from the shareholders’ preferential rights, a valid resolution under this item 9 requires that the resolution be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the EGM. This resolution is not conditional upon any other item on the agenda, and no other item is conditional upon this item 9. The shares under this item 9 fall within the limit of 390,000,000 shares described under item 6 and have been deducted in calculating the maximum number of shares under that item. The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make such minor adjustments to the resolution as may prove necessary in connection with registration of the resolution with the Swedish Companies Registration Office and Euroclear Nordics AB.

Miscellaneous

The Board of Directors, or a person appointed by the Board of Directors, will be authorised to make minor changes to the resolutions under items 6 to 9 on the agenda as may prove necessary in connection with registration of the resolutions with the Swedish Companies Registration Office and Euroclear Nordics AB, including adjusting the maximum numbers of shares under items 6 to 9 to take account of any additional shares issued and registered before the EGM.

Complete proposals and documentation in accordance with the Swedish Companies Act (2005:551), including the Board of Directors’ statement pursuant to Chapter 13, Section 7 of the Swedish Companies Act and the auditor’s report on that statement pursuant to Chapter 13, Section 8 of the Swedish Companies Act, will be kept available at the Company’s office as well as at the Company’s website www.inq.ai no later than 9 October 2026 and up to and including the day of the EGM, and will be sent free of charge to those shareholders who request it and provide their postal address.

According to Chapter 7, section 32 of the Swedish Companies Act, at a general meeting the shareholders are entitled to require information from the Board of Directors and the CEO regarding circumstances which may affect items on the agenda and circumstances which may affect the Company’s financial situation.

For information on how personal data is processed, see www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Number of shares and votes in the Company

As of the date of this notice, the total number of ordinary shares and votes in the Company was 1,102,362,753. The Company is not holding any own shares.

Stockholm, 8 October 2026

INQ Group AB (publ)

The Board of Directors

Attachment

INQ_EGM_2026_Notice_SWE

Posted in UncategorizedTagged GlobeNewswire

Notice to attend Extraordinary General Meeting in INQ Group AB (publ)

Posted on October 8, 2026 by Ravi Shankar

Purpose of the EGM
The Board is proposing three things:

Warrants and convertibles within the existing limit. The AGM 2026 authorised the Board to issue new shares only. Authorisations at previous annual general meetings also covered warrants and convertibles. The proposal restores that flexibility, within the same 390,000,000 limit, giving the Board the full range of instruments to raise capital on the best available terms and to meet the needs of different types of investors.
Conversion of Tranche 7 by the Board and management. The Chairman, the Chief Executive Officer and other members of management have taken part in Tranche 7 of the Company’s convertible loan by setting off accrued fees and salary instead of taking them in cash. Tranche 7 converts at SEK 0.16 per share. Because they are directors and employees, shares issued to them on conversion require shareholder approval. The EGM is also asked to approve conversion of Tranche 7 by the other participants. All shares on conversion of Tranche 7 are counted within the 390,000,000 limit.
Reverse split after conversion of Tranches 1 to 5. As resolved by the AGM 2026, the 1:100 reverse split was to be carried out before the share capital measures and the issue of shares on conversion of Tranches 1 to 5 of the convertible loan. The proposal allows the reverse split to take place after those shares have been issued, at the quota value applying at that time, with the Board setting the timing.

Kevin Adeson, Chairman of INQ Group AB, commented:

Notification of participation

Shareholders wishing to attend the EGM must:

be entered as shareholders in the share register maintained by Euroclear Nordics AB no later than on Thursday, 22 October 2026; and
notify the Company of their intention to participate no later than on Monday, 26 October 2026.

Proxies

Proposed agenda

Opening of the Meeting and election of Chairman
Preparation and approval of voting list
Approval of the agenda
Election of one or two persons to verify the minutes
Determination of whether the Meeting has been duly convened
Resolution on an authorisation for the Board of Directors to resolve on the issue of new shares, warrants and convertibles
Resolution on amendment of the resolution on consolidation of shares (reverse split 1:100) adopted by the Annual General Meeting 2026
Resolution on a directed issue of new shares with payment by set-off to members of the Board of Directors and the Chief Executive Officer in respect of participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement
Resolution on a directed issue of new shares with payment by set-off to other subscribers for participations in Tranche 7 under the Amended and Restated Secured Convertible Agreement
Closing of the Meeting

Proposals

Opening of the Meeting and election of Chairman (item 1)

The Board of Directors proposes that Jörgen S. Axelsson, or in his absence the person appointed by the Board of Directors, be elected as Chairman of the Meeting.

Authorisation for the Board of Directors to resolve on the issue of new shares, warrants and convertibles (item 6)

Resolution on amendment of the resolution on consolidation of shares (reverse split 1:100) adopted by the Annual General Meeting 2026 (item 7)

Directed issue of new shares with payment by set-off to members of the Board of Directors and the Chief Executive Officer in respect of participations in Tranche 7 (item 8)

Directed issue of new shares with payment by set-off to other subscribers for participations in Tranche 7 (item 9)

Miscellaneous

For information on how personal data is processed, see www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Number of shares and votes in the Company

As of the date of this notice, the total number of ordinary shares and votes in the Company was 1,102,362,753. The Company is not holding any own shares.

Stockholm, 8 October 2026

INQ Group AB (publ)

The Board of Directors

Attachment

INQ_EGM_2026_Notice_SWE

Posted in UncategorizedTagged GlobeNewswire

INQ substantially deleverages its balance sheet as secured lenders convert USD 5.4 million of convertible debt into shares

Posted on October 8, 2026 by Ravi Shankar

INQ Group AB (publ) (“INQ” or the “Company”) today announces that holders of its senior secured convertible loan have elected to convert approximately USD 5.43 million of principal and accrued interest into equity, reducing the principal outstanding under the loan by more than three quarters, from approximately USD 6.7 million to approximately USD 1.55 million. Around 78 per cent of the new shares will be held by the Company’s two largest shareholders and by its directors, management and employees, whom are existing, long-standing investors in INQ.

The holders are converting approximately USD 5.15 million of principal, together with approximately USD 0.28 million of accrued interest (USD 5.43 million in total), into 811,913,347 new shares in INQ Group AB at a conversion price of SEK 0.06 per share (at the fixed exchange rate of SEK 9.05 per USD under the loan agreement). Of the amount converted by UK employees, a portion corresponding to 7,133,042 shares is being settled in cash to meet tax withholding obligations and is not included in the number of new shares set out above.

Holders of approximately 97.2 per cent of the aggregate principal amount outstanding under Tranches 1 to 5 have elected to convert. The balance remaining outstanding under the convertible loan is held across Tranches 4, 5, 6 and 7.

Including the accrued interest converted, the Company’s interest-bearing debt will be reduced by approximately USD 5.43 million.

The conversion deleverages the Company and transforms the quality of its balance sheet. It involves no material cash outflow for the Company and reduces the Company’s future interest costs. The Board of Directors believes that a stronger balance sheet improves the Company’s position in the ongoing discussions with commercial partners and suppliers and provides a stronger platform for future growth. The two largest shareholders in the Company following the conversion are the same as the two largest shareholders prior to it.

Jonathan Faiman, Chief Executive Officer of INQ Group AB, commented:

“This conversion substantially reduces our debt and positions our company to take advantage of the strategic opportunities ahead of us. The convertible loan is largely held by existing long term shareholders who have backed the Company through its transformation. Also holding this convertible are members of our Board, our management team and our employees. With a stronger balance sheet, the Company is ready for its next phase of growth in new channels, like education, and in new geographies.”

The conversion comes as inq continue to pursue significant commercial transactions for the remainder of 2026 across its consumer and enterprise businesses.

The LAMY Edition inq-01 is progressing towards commercial availability ahead of the holiday selling period, building on the first commercial order announced earlier this year. inq is also preparing inventory of its own products ahead of the holiday period as the Company focuses on increasing product availability and supporting consumer demand.

Kevin Adeson, Chairman of INQ Group AB, commented:

“The significance of this conversion is the alignment it creates. With a substantially stronger balance sheet, INQ is moving from building the foundations of its strategy towards commercial execution across products, partnerships and enterprise opportunities. The holders of the convertible understand this and want to be in a position to benefit from the value creation.”

The conversion will result in the issuance of 811,913,347 new shares, increasing the total number of shares in the Company from 1,102,362,753 to 1,914,276,100. As resolved by the annual general meeting on 31 July 2026, the new share issues are carried out together with a reduction of the share capital by SEK 77,165,392.71, lowering the quota value of each share from SEK 0.13 to SEK 0.06 so that it does not exceed the conversion price, followed by a bonus issue of SEK 77,165,392.71 without issue of new shares and a further reduction of the share capital to the extent required for the quota value to correspond to a whole number of öre.

Following registration, the Company’s share capital will amount to SEK 191,427,610.00, corresponding to a quota value of SEK 0.10 per share, and the sequence entails no reduction of the Company’s share capital.

The new shares are issued in two steps resolved on different legal bases. 184,731,709 of the new shares are subscribed for by members of the Board of Directors, employees and contractors under the directed issue with payment by set-off resolved by the annual general meeting under item 14(d), being an issue to the category of persons covered by Chapter 16 of the Swedish Companies Act. The remaining 627,181,638 new ordinary shares are issued to holders who have requested conversion and who do not belong to that category, together with the conversion of a cash investment made by one member of the Board of Directors in his capacity as a lender, pursuant to a resolution of the Board of Directors on 6 October 2026 under the authorisation granted by the annual general meeting under item 14(c), with payment in each case by way of set-off of the claim represented by the relevant convertible note.

The total number of shares following the conversion is divisible by 100 in preparation for the 1:100 reverse share split resolved by the annual general meeting. The Company intends to carry out the reverse share split as soon as practicable after the new shares have been registered and delivered to the converting holders, following which the Company will have 19,142,761 shares in issue.

The conversion is being undertaken in accordance with the terms of the convertible loan agreement, the directed set-off issue resolved by the annual general meeting held on 31 July 2026 and the authorisation granted to the Board of Directors by that meeting to resolve on the issue of new shares to enable conversion.

Following registration of the new shares with the Swedish Companies Registration Office, the conversion will be reflected in the Company’s registered share capital and number of shares.

For further information, please contact:

Jonathan Faiman
Chief Executive Officer
INQ Group AB (publ)

About INQ Group AB

INQ Group AB (publ) is a Swedish technology company developing intelligent digital writing solutions that connect natural handwriting with modern digital workflows. The INQ platform combines connected writing hardware, software and AI-enabled capabilities across consumer, enterprise and education markets.

This information is information that INQ Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 8 October 2026 at 07:45 CEST.

Attachment

INQ_Convertible_conversion_press_release_08_10_2026_SV

Posted in UncategorizedTagged GlobeNewswire

Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance

Posted on October 8, 2026 by Ravi Shankar

Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales

COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year 2026, reflecting stronger-than-expected performance in its Travel Health business.

Revenue from Travel Health is now expected to reach approximately DKK 3,400 million, compared to previous guidance of approximately DKK 3,000 million. The increase is primarily driven by higher rabies vaccine sales, particularly in the United States, where increased animal rabies activity has led to a significant rise in human exposure and a corresponding increase in demand for both pre- and post-exposure vaccination.

All other revenue assumptions remain unchanged from the guidance issued on August 21, 2026. This includes approximately DKK 2.500 million from the Public Preparedness business, of which approximately DKK 2,400 million has been secured in orders to-date. As a result, total revenue for 2026 is now expected to be approximately DKK 6,100 million, while the EBITDA margin is expected to be approximately 32%, compared to previous guidance of approximately 30%.

All other assumptions underpinning the 2026 financial guidance, as outlined in the 2025 Annual Report, remain unchanged.

2026 financial guidance, history of changes

DKK million	New as of 08-Oct	Updated 21-Aug	Updated 11-May	Original
Revenue	~6,100	~5,700	5,500 – 5,700	5,000 – 5,200
Travel Health	~3,400	~3,000	~3,000	~3,000
Public Preparedness	~2,500	~2,500	2,300 – 2,500	1,800 – 2,000
Other revenue	200	200	200	200
EBITDA margin	~32%	~30%	~28%	25%

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 48 / 2026

This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.

Attachment

Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance

Posted in UncategorizedTagged GlobeNewswire

Date of virtual 2026 Annual Meeting of Stockholders Announced by Reading International, Inc.

Posted on October 8, 2026 by Ravi Shankar

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) — Reading International, Inc. (NASDAQ: RDI, RDIB) today announced it will hold its 2026 Annual Meeting of Stockholders on Thursday, December 3, 2026, beginning at 2:00 p.m. Eastern Time. The formal portion of the meeting will be followed by a management presentation and a stockholder question and answer session.

The Annual Meeting will be held virtually, hosted by Computershare, Inc. The record date for registered stockholders and duly appointed proxyholders entitled to attend the Annual Meeting is October 15, 2026. Registered stockholders who log into the virtual meeting with a control number will be able to listen to the audio webcast, and view presentation materials. Only registered Class B stockholders will be able to communicate, participate in, and vote at the Annual Meeting. Details of how to register for and access the Annual Meeting will be provided in the Company’s 2026 definitive Proxy Statement.

The Company anticipates commencing electronic mailing of the notice of the 2026 Annual Meeting and definitive 2026 Proxy Statement on or about the close of business on October 22, 2026, to stockholders of record as of the record date.

The 2026 Proxy Statement and the management presentation presented at the Annual Meeting will be available for viewing on the Company’s website, Investors.Readingrdi.com.

About Reading International, Inc.

Reading International, Inc. (NASDAQ: RDI, RDIB), an internationally diversified cinema and real estate company operating through various domestic and international subsidiaries, is a leading entertainment and real estate company, engaging in the development, ownership, and operation of cinemas and retail and commercial real estate in the United States, Australia, and New Zealand.

Reading’s cinema subsidiaries operate under multiple cinema brands: Reading Cinemas, Consolidated Theatres and the Angelika brand. The Company’s live theatres are owned and operated by its Liberty Theaters subsidiary, under the Orpheum and Minetta Lane names. The Company’s signature property developments, including Newmarket Village in Brisbane, Australia, and 44 Union Square in New York City, are maintained in special purpose entities.

Additional information about Reading can be obtained from the Company’s website: ReadingRDI.com.

For investor information contact:
Reading International, Inc.
Gilbert Avanes, Executive Vice President & Chief Financial Officer
(213) 235-2240

For media information contact:
Joele Frank, Wilkinson Brimmer Katcher
Kelly Sullivan
(212) 355-4449

Posted in UncategorizedTagged GlobeNewswire

Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range

Posted on October 8, 2026 by Ravi Shankar

Regulated information – inside information
Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET

Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range

Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 30 September 2026.

Key Highlights

Revenue of €281.3 million, up 23.2% (19.5% at CER¹), supported by strong performance in EMEA, Latin America and Brands & Essentials (B&E) in North America–Pacific, together with contribution from acquisitions
Organic growth at CER of 3.4%, led by EMEA (6.5%), Latin America (9.7%) and B&E in North America–Pacific (26.1%)
Compounding Services in North America–Pacific was impacted by the temporary, industry-wide IV bag recall. The situation has now stabilized, and we expect volumes to transition to normalized levels through Q4
Completed the acquisition of Injeplast in Brazil; all previously announced acquisitions are now closed, with integration on track
FY 2026 revenue outlook confirmed to €1,125 – €1,150 million with an adj. EBITDA margin of 19.5% – 20.0%
Fagron will host its Capital Markets Day at the FSS facility in Wichita, Kansas, in October 2027

Rafael Padilla, CEO of Fagron:

“Our third quarter shows the strength of our diversified model. In EMEA, growth was led by Compounding Services, driven by new customer wins and rising underlying demand, while in Latin America, performance was supported by a successful Consulfarma fair and our acquisitions in Brazil added further momentum.

In North America–Pacific, Brands & Essentials delivered another strong quarter, while Compounding Services was held back by the industry-wide IV bag recall. Supply has now stabilized, and we expect volumes to recover progressively through the fourth quarter.

With Injeplast completed, all previously announced acquisitions are now closed and integrating well. Our M&A pipeline remains strong, with a clear focus on disciplined, value-accretive opportunities to strengthen our global leadership.

For 2026, we expect revenue of €1,125 – €1,150 million with an adj. EBITDA margin of 19.5% – 20.0%. We believe North America–Pacific has reached an inflection point. As IV bag volumes recover, maintaining our quality leadership, our expansion projects come on stream and our acquisitions contribute fully, we are well positioned for a strong 2027. Our mid-term objectives remain unchanged.”

¹ Constant exchange rate

Webcast
Rafael Padilla (CEO) and Karin de Jong (CFO) will discuss the trading update in a webcast starting at 9.30 AM CET. Registration to the webcast is available via this link. The presentation for the call will be available to download from the Fagron website around 7.00 AM CET.

Further information
Ignacio Artola
Global Head of Investor Relations
Tel. +34 670385795
Ignacio.artola@fagron.com

Attachment

Fagron – Q3 2026 Trading Statement PR EN

Posted in UncategorizedTagged GlobeNewswire

Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Posted on October 8, 2026 by Ravi Shankar

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, October 8, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical development. NTX-253 is a positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia.

“Completing Phase 1 and the decision by Neurosterix to progress NTX-253 into Phase 2 studies in schizophrenia patients is a significant achievement,” said Tim Dyer, CEO of Addex. “The well-designed study combining healthy volunteers and schizophrenia patients within a single study has provided important safety and pharmacokinetic data.”

The clinical study includes a multi-part, ascending-dose design intended to efficiently characterize NTX-253’s clinical profile and support subsequent patient-focused development. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) components, incorporating key translational elements such as food-effect and cerebrospinal fluid (CSF) assessments. The studies included both healthy volunteers and stable schizophrenia patients, and has provided important safety and pharmacokinetic data.

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with Perceptive Advisors. Addex retains a 20% equity interest in Neurosterix.

About NTX-253 and M4 PAMs

The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is a potent, selective, oral PAM of M4 that fine-tunes muscarinic signaling with the potential to reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists. Preclinical studies demonstrate robust antipsychotic-like activity and a favorable safety profile.

About Addex Therapeutics

Addex Therapeutics s a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is also advancing an differentiated GABAB PAM compound for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has also invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.

Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.com

Mike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Posted in UncategorizedTagged GlobeNewswire

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren’s Disease

Posted on October 8, 2026 by Ravi Shankar

October 8, 2026, 7:00 AM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease.

The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded that the UNITY study is unable to meet its primary endpoint. Safety was consistent with efgartigimod’s established profile and no new safety signals were identified.

“We are disappointed by this outcome, most of all for people living with Sjögren’s disease, who are still waiting for treatments that fundamentally change the course of their disease,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. “Sjögren’s Disease is one of the most heterogeneous and complicated diseases in immunology, and unraveling the biology of complex diseases is at the heart of what we do. We will analyze these data in depth and share what we learn with the Sjögren’s community. We are grateful to the patients, families, investigators and site staff who made this study possible.”

Following study close and database lock, argenx will conduct a comprehensive analysis of the data to understand the study’s outcome and generate insights that may inform future research in Sjögren’s disease.

UNITY Study Design
UNITY is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension, designed to evaluate the efficacy, safety and tolerability of efgartigimod SC in adults with moderate-to-severe Sjögren’s disease. To be eligible, patients had to meet the 2016 ACR/EULAR classification criteria for primary Sjögren’s disease, test positive for anti-Ro/SSA autoantibodies and have moderate-to-severe systemic disease activity (clinESSDAI ≥6) while receiving stable background standard of care. Patients were randomized 1:1 to receive weekly efgartigimod SC or placebo during the double-blind treatment period. The primary endpoint was change from baseline in systemic disease activity, as measured by the clinical EULAR Sjögren’s Syndrome Disease Activity Index (clinESSDAI), at Week 48. Key secondary endpoints included the proportion of patients achieving low disease activity (clinESSDAI <5), responder status on the Sjögren’s Tool for Assessing Response (STAR), change in patient-reported symptoms as measured by the Diary of Sjögren’s Symptoms Assessment (DiSSA), and safety and tolerability.

About Sjögren’s Disease
Sjögren’s disease is a chronic, slowly progressive, inflammatory systemic autoimmune disease characterized by immune-mediated destruction of the exocrine glands. It can be severely debilitating and have a negative impact on patient quality of life, with commonly reported symptoms including dry eyes and mouth, fatigue and joint pain. In addition, a substantial subset of patients suffer from extraglandular systemic disease. While the presence of anti-Ro and IgG autoantibodies is considered a hallmark of the disease, its underlying cause is believed to be multifactorial, with environmental triggers leading to autoimmunity and chronic inflammation. The disease predominantly affects women, with a 9:1 female-to-male incidence ratio. Given its heterogeneous nature, the treatment journey can be challenging, with long delays and high rates of misdiagnosis.

About VYVGART
VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART Hytrulo® is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics.

VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions.

About argenx
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:
Colin McBean
cmcbean@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com

Forward-Looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements generally can be identified by the use of forward-looking words, such as “aim”, “anticipate”, “aspire”, “believe”, “can”, “continue”, “could”, “estimate”, “expect”, “entail”, “forecast”, “future”, “goals”, “hope”, “intend”, “is designed to”, “likely”, “may”, “might”, “objective”, “plan”, “possible”, “potential”, “pursue”, “project”, “predict”, “seek”, “should”, “strategy”, “target”, “will” and other words and terms of similar meaning and expression, including in connection with any discussion of future operating or financial performance. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development risks and setbacks; interpretation of argenx’s clinical trial data by regulatory authorities and argenx’s ability to obtain regulatory approval; the risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials; the occurrence of adverse safety events or participant dropouts; the acceptance of its products and product candidates by its patients as safe, effective, and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; the impact of healthcare regulations, including rules on reimbursement for argenx’s products; competition in drug discovery, development and commercialization efforts; its reliance on third-party suppliers, service providers and manufacturers; and instability and conflicts in the regions in which the company has suppliers or markets for its products. A further list and description of these and other risks, uncertainties, and factors that could cause actual results to differ materially from those referred to in the forward-looking statements can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these risks and uncertainties, the reader is advised not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Posted in UncategorizedTagged GlobeNewswire

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

Posted on October 8, 2026 by Ravi Shankar

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)
First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease
argenx plans to advance FB102 into Phase 3 development

October 8, 2026, 7:00 AM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following argenx’s acquisition of Forte Biosciences in August 2026.

Patients treated with FB102 demonstrated a statistically significant and clinically relevant treatment effect compared to placebo. The study met its primary endpoint of change from baseline in the ratio of villus height–to–crypt depth (Vh:Cd) at day 78 versus placebo in adults with celiac disease undergoing a gluten challenge (p=0.0176). Broad efficacy measures, including intraepithelial lymphocyte (IEL) density, villus height-to-crypt depth intraepithelial lymphocyte (VCIEL) composite score, and symptoms, were consistent with the primary endpoint, providing additional evidence of effect across histologic, inflammatory, and clinical measures.

The observed safety profile was consistent with prior studies and the known safety profile of FB102, with no new safety signals identified.

“These positive Phase 2 results strengthen our conviction in the potential of FB102 to address a significant unmet need for people living with celiac disease, where there are currently no approved therapies,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. “The study builds on the Phase 1b trial, providing consistent clinical evidence that CD122 blockade can protect against gluten-induced intestinal damage and prevent emergence of patient symptoms, even under a more intense gluten challenge, validating CD122 as a promising therapeutic target in celiac disease. Combined with the consistent safety profile observed across studies, these findings support advancing FB102 into Phase 3 development and further exploring its broader potential across immune-mediated diseases.”

Detailed results from the Phase 2 study will be shared at an upcoming medical meeting. FB102 continues to be evaluated as a potential treatment in other autoimmune diseases, including vitiligo and alopecia areata.

FB102-301 Study Design
FB102-301 (NCT06982963) is a randomized, double-blind, placebo-controlled, Phase 2 study evaluating FB102 in adults with celiac disease. The study enrolled 126 patients with confirmed celiac disease who were symptom free on a strict gluten-free diet for at least 12 months. Participants were randomized (2:2:1) to receive intravenous infusions of FB102 (two dose levels) or placebo while undergoing a controlled, eight-week oral gluten challenge. The primary endpoint was change from baseline in the ratio of villus height-to-crypt depth (Vh:Cd) at day 78 versus placebo, aimed at determining whether FB102 protects the intestine from gluten-induced damage over the challenge period.

About Celiac Disease
Celiac disease is a chronic autoimmune condition triggered by ingesting gluten, a group of proteins found in wheat, barley, and rye. In people with celiac disease, gluten triggers an immune response that damages the lining of the small intestine. Over time, this damage leads to impaired nutrient absorption and symptoms that include abdominal pain, bloating, diarrhea, and fatigue. There are no approved medicines to treat celiac disease and the current standard of care is a strict gluten-free diet. Unintended exposure to gluten through consumer products, like prepackaged foods, cosmetics, toothpaste, vitamins, and nutritional supplements, is common. Many people living with celiac disease also experience challenges eating out of the home at restaurants, work, or while traveling, which impacts their quality of life. It is estimated that approximately 1 percent of people worldwide have celiac disease, and studies show the incidence is rising by about 7.5% per year. The burden of symptoms, growing prevalence, and lack of any approved therapeutic options reinforce the critical need for medications that can address the underlying causes of intestinal damage and improve symptoms and outcomes in people living with celiac disease.

About FB102
FB102 is an investigational, first-in-class anti-CD122 antibody being studied as a potential treatment for several autoimmune diseases, including celiac disease, vitiligo, and alopecia areata. CD122 is a key component of IL-2 and IL-15 signaling pathways involved in the activation and maintenance of disease-driving immune cells. FB102 is designed to block CD122 to selectively modulate IL-2 and IL-15 pathways that cause inflammation while preserving regulatory T-cell function and immune balance. The U.S. Food and Drug Administration has granted FB102 Fast Track Designation for celiac disease.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:
Suzanne Johnson 
sjohnson@argenx.com

Investors:
Alexandra Roy
aroy@argenx.com

Forward Looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements generally can be identified by the use of forward-looking words, such as “aim”, “anticipate”, “aspire”, “believe”, “can”, “continue”, “could”, “estimate”, “expect”, “entail”, “forecast”, “future”, “goals”, “hope”, “intend”, “is designed to”, “likely”, “may”, “might”, “objective”, “plan”, “possible”, “potential”, “pursue”, “project”, “predict”, “seek”, “should”, “strategy”, “target”, “will” and other words and terms of similar meaning and expression, including in connection with any discussion of future operating or financial performance. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development risks and setbacks; interpretation of argenx’s clinical trial data by regulatory authorities and argenx’s ability to obtain regulatory approval; the risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials; the occurrence of adverse safety events or participant dropouts; the acceptance of its products and product candidates by its patients as safe, effective, and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; the impact of healthcare regulations, including rules on reimbursement for argenx’s products; competition in drug discovery, development and commercialization efforts; its reliance on third-party suppliers, service providers and manufacturers; and instability and conflicts in the regions in which the company has suppliers or markets for its products. A further list and description of these and other risks, uncertainties, and factors that could cause actual results to differ materially from those referred to in the forward-looking statements can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these risks and uncertainties, the reader is advised not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Posted in UncategorizedTagged GlobeNewswire

TGS Q3 2026 Operational Update

Posted on October 8, 2026 by Ravi Shankar

OSLO, Norway (8 October 2026) – TGS, a leading global provider of energy data and intelligence, routinely publishes a quarterly operational update six working days after quarter-end.

The table below shows TGS’ normalized Ocean Bottom Node (OBN) crew count¹:

	Q3 2026	Q3 2025
Normalized crew count Contract¹	2.2	1.8
Normalized crew count Multi-client¹	0.0	1.0

^{1) The table shows the average number of crews in operation when assuming a normalized crew size.}

The table below shows TGS’ allocation of active seismic streamer 3D vessel capacity².

	Q3 2026	Q3 2025
Contract	53%	45%
Multi-client	22%	28%
Steaming	18%	10%
Yard	7%	8%
Standby	0%	9%
Number of vessels	6	6

^{2) The statistics include active seismic 3D streamer vessels (capacity working on site characterization projects is excluded).}

Based on preliminary financial review, TGS expects multi-client investment to be approximately USD 63 million in Q3 2026, compared to USD 85.9 million in Q3 2025.

Kristian Johansen, CEO of TGS, commented: “The normalized Ocean Bottom Node (OBN) crew count in Q3 was 2.2, slightly above expectations. During the quarter, TGS completed an OBN contract in the Gulf of America for a client where we have a long-term capacity agreement and a node-on-a-rope contract in Europe. Despite high streamer 3D vessel booking going into Q3, utilization came in lower than expected due to operational challenges on a North Sea multi-client project that was completed in September. Looking ahead, we expect streamer 3D vessel utilization to remain high, with all our streamer 3D vessel capacity booked for Q4.”

TGS will release its Q3 2026 results at 07:00 a.m. CEST on 22 October 2026. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 a.m. CEST, webcasted live.

The webcast can be followed live via this link:
https://qcnl.tv/p/F9pp7ArbItpZ5nPyrrIErw

For more information, visit TGS.com (http://www.tgs.com) or contact:
Bård Stenberg, VP IR & Business Intelligence
Tel.: +47 992 45 235
E-mail: investor@tgs.com

About TGS
TGS provides advanced data and intelligence to companies active in the energy sector. With leading-edge technology and solutions spanning the entire energy value chain, TGS offers a comprehensive range of insights to help clients make better decisions. Our broad range of products and advanced data technologies, coupled with a global, extensive and diverse energy data library, make TGS a trusted partner in supporting the exploration and production of energy resources worldwide. For further information, please visit www.tgs.com (https://www.tgs.com/).

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict and are based upon assumptions as to future events that may not prove accurate. These factors include volatile market conditions, investment opportunities in new and existing markets, demand for licensing of data within the energy industry, operational challenges, and reliance on a cyclical industry and principal customers. Actual results may differ materially from those expected or projected in the forward- looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.

Posted in UncategorizedTagged GlobeNewswire